All Articles

Browse all articles — filter by topic, how strong the science is, or date.

Showing 673–696 of 767 in Treatments & Drugs

Apr 2, 2026investor.lilly.com

La FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o agua

generalTreatments & Drugs

Apr 2, 2026globenewswire.com

Assisted Reproductive Technology Market Set to Reach $6.02 Billion by 2030 | MarketsandMarkets™

generalTreatments & Drugs

Apr 2, 2026sciencedaily.com

Breakthrough could protect the vision cells that let you see faces and colors

generalTreatments & Drugs

Apr 2, 2026globenewswire.com

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer

generalTreatments & Drugs

Apr 2, 2026globenewswire.com

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

generalTreatments & Drugs

Apr 2, 2026globenewswire.com

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

generalTreatments & Drugs

Apr 2, 2026globenewswire.com

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

generalTreatments & Drugs

Apr 1, 2026investor.lilly.com

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

significantTreatments & Drugs

Apr 1, 2026sciencedaily.com

Millions start work too early. This drug helps them stay awake

significantTreatments & Drugs

Apr 1, 2026longevity.technology

New data show TrenibotE safety in repeat treatments

landmarkTreatments & Drugs

Mar 31, 2026lifespan.io

Modified Immune Cells Target Cancer’s Metabolic Signature

noteworthyTreatments & Drugs

Mar 31, 2026lifespan.io

Modified Immune Cells Target Cancer’s Metabolic Signature

significantTreatments & Drugs

Mar 30, 2026longevity.technology

Lilly races to become first longevity Big Pharma

noteworthyTreatments & Drugs

Mar 30, 2026sciencedaily.com

Simple therapies beat drugs for knee arthritis pain relief

significantTreatments & Drugs

Mar 30, 2026academic.oup.com

Effectiveness of non-pharmacological and pharmacological interventions in preventing delirium in older adults: a systematic review and meta-analysis of randomised controlled trials

significantTreatments & Drugs

Mar 28, 2026investor.lilly.com

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

landmarkTreatments & Drugs

Mar 27, 2026fightaging.org

Complicating 7-Ketocholesterol in Aging and Disease

generalTreatments & Drugs

Mar 27, 2026lifespan.io

Rubedo Announces Positive Preliminary Results for RLS-1496

significantTreatments & Drugs

Mar 27, 2026longevity.technology

Rubedo reports early clinical signal for senotherapeutic drug

significantTreatments & Drugs

Mar 27, 2026longevity.technology

Maze Therapeutics reports positive phase 2 data for MZE829

significantTreatments & Drugs

Mar 27, 2026longevity.technology

Rubedo reports positive phase 1 results for RLS-1496

landmarkTreatments & Drugs

Mar 27, 2026nature.com

Mining the prodrome of neurodegeneration

significantTreatments & Drugs

Mar 26, 2026longevity.technology

Research links GLP-1s to osteoporosis and gout risks

significantTreatments & Drugs

Mar 26, 2026lifespan.io

Cellular Senescence and Senotherapeutics: The Expert Roundup

significantTreatments & Drugs